Based on the results of two recent papers, including the CONVERT trial, what have we learned about when amikacin liposome inhalation suspension should be considered in patients with MAC lung disease?

Based on the results of two recent papers, including the CONVERT trial, what have we learned about when amikacin liposome inhalation suspension should be considered in patients with MAC lung disease?

CLICK HERE FOR CME CREDIT

Based on the results of two recent papers, including the CONVERT trial, what have we learned about when amikacin liposome inhalation suspension should be considered in patients with MAC lung disease?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Stephen Ruoss, MD

Stephen Ruoss, MD

Clinical Chief, Pulmonary and Critical Care Medicine Division
Department of Medicine
Medical Director, Stanford Medical Center Respiratory Care Services, Stanford Medical Center
Medical Director, Stanford Medical Center Transfer Center,
Stanford Univer